Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy

Prostate Cancer and Prostatic Diseases volume 17, pages 199–205 (2014)Cite this article

Subjects

Abstract

Background:

Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from renal cell carcinoma (RCC) tissue that has been associated with RCC metastasis. However, in prostate cancer, the expression of DSGb5 has not yet been fully assessed. In this study, we investigated DSGb5 expression in prostate tissues and the relationship between DSGb5 expression and clinicopathological characteristics of prostate cancer patients.

Methods:

A total of 130 patients who underwent radical prostatectomy (RP) at our hospital between January 2005 and December 2007 were analyzed in this study. The expression of DSGb5 in prostatectomy specimens was examined by immunohistochemical analysis with monoclonal antibody 5F3 (anti-DSGb5). Associations between 5F3 expression and clinicopathological findings were investigated and the factors that affected PSA failure-free survival were assessed by Kaplan–Meier analysis and a Cox regression model.

Results:

When immunoreactivities of 5F3 were measured, negative to strong staining was observed in prostate cancer tissue, whereas strong staining was observed in benign prostate glands. These expression patterns suggest that DSGb5 may act as a differentiation antigen in cancerization. The PSA failure-free survival was significantly higher in the 5F3 intact expression group than in the 5F3 reduced expression group (log-rank P=0.0220). On multivariate analysis, 5F3 intact expression showed significantly worse PSA failure-free survival following RP.

Conclusions:

5F3 expression reflects the clinical and pathological features of prostate cancer and is correlated with the outcomes following RP. Further studies are necessary to clarify the functional roles of DSGb5 and establish a novel biomarker for prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747–752.

    Article  CAS  PubMed  Google Scholar 

  2. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P . Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538–542.

    Article  CAS  PubMed  Google Scholar 

  3. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA . How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006; 175: 1337–1340.

    Article  PubMed  Google Scholar 

  4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

    Article  CAS  PubMed  Google Scholar 

  5. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938–1942.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr. FJ, Dotan ZA, DiBlasio CJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005–7012.

    Article  PubMed  Google Scholar 

  7. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766–771.

    Article  CAS  PubMed  Google Scholar 

  8. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC . Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517–523.

    Article  PubMed  Google Scholar 

  9. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 2005; 173: 1126–1131.

    Article  PubMed  Google Scholar 

  10. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML . Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179: 1354–1360 discussion 1351–1360.

    Article  PubMed  Google Scholar 

  11. Hakomori S . Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989; 52: 257–331.

    Article  CAS  PubMed  Google Scholar 

  12. Hakomori S . Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996; 56: 5309–5318.

    CAS  PubMed  Google Scholar 

  13. Ishimura H, Takahashi T, Nakagawa H, Nishimura S, Arai Y, Horikawa Y et al. N-acetylglucosaminyltransferase V and beta1-6 branching N-linked oligosaccharides are associated with good prognosis of patients with bladder cancer. Clin Cancer Res 2006; 12: 2506–2511.

    Article  CAS  PubMed  Google Scholar 

  14. Saito S, Orikasa S, Ohyama C, Satoh M, Fukushi Y . Changes in glycolipids in human renal-cell carcinoma and their clinical significance. Int J Cancer 1991; 49: 329–334.

    Article  CAS  PubMed  Google Scholar 

  15. Saito S, Levery SB, Salyan ME, Goldberg RI, Hakomori S . Common tetrasaccharide epitope NeuAc alpha 2–>3Gal beta 1—>3(Neu-Ac alpha 2—>6)GalNAc, presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities. J Biol Chem 1994; 269: 5644–5652.

    CAS  PubMed  Google Scholar 

  16. Ito A, Levery SB, Saito S, Satoh M, Hakomori S . A novel ganglioside isolated from renal cell carcinoma. J Biol Chem 2001; 276: 16695–16703.

    Article  CAS  PubMed  Google Scholar 

  17. Saito S, Orikasa S, Satoh M, Ohyama C, Ito A, Takahashi T . Expression of globo-series gangliosides in human renal cell carcinoma. Jpn J Cancer Res 1997; 88: 652–659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kawasaki Y, Ito A, Withers DA, Taima T, Kakoi N, Saito S et al. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells. Glycobiology 2010; 20: 1373–1379.

    Article  CAS  PubMed  Google Scholar 

  19. Ito A, Handa K, Withers DA, Satoh M, Hakomori S . Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett 2001; 504: 82–86.

    Article  CAS  PubMed  Google Scholar 

  20. Saito S, Egawa S, Endoh M, Ueno S, Ito A, Numahata K et al. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer. Int J Cancer 2005; 115: 105–113.

    Article  CAS  PubMed  Google Scholar 

  21. Ito A, Saito S, Masuko T, Oh-Eda M, Matsuura T, Satoh M et al. Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues. Glycoconj J 2001; 18: 475–485.

    Article  CAS  PubMed  Google Scholar 

  22. Gerdes J, Schwab U, Lemke H, Stein H . Production of a mouse monoclonal-antibody reactive with a human nuclear antigen associated with cell-proliferation. Int J Cancer 1983; 31: 13–20.

    Article  CAS  PubMed  Google Scholar 

  23. Brawer MK, Peehl DM, Stamey TA, Bostwick DG . Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45: 3663–3667.

    CAS  PubMed  Google Scholar 

  24. Varma M, Linden MD, Amin MB . Effect of formalin fixation and epitope retrieval techniques on antibody 34betaE12 immunostaining of prostatic tissues. Mod Pathol 1999; 12: 472–478.

    CAS  PubMed  Google Scholar 

  25. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437–441.

    Article  CAS  PubMed  Google Scholar 

  26. Epstein JI, Allsbrook Jr. WC, Amin MB, Egevad LL . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.

    Article  PubMed  Google Scholar 

  27. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual 6th edn. Springer-Verlag: New York, NY, 2002.

    Book  Google Scholar 

  28. Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB et al. Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J 1983; 2: 2355–2361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yee DS, Shariat SF, Lowrance WT, Maschino AC, Savage CJ, Cronin AM et al. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int 2011; 108: 502–507.

    Article  PubMed  Google Scholar 

  30. Gleason DF, Mellinger GT . Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58–64.

    Article  CAS  PubMed  Google Scholar 

  31. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H . Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001; 166: 1692–1697.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (grants no. 21390437 and 25462465 to YA and AI, respectively).

Author information

Authors and Affiliations

  1. Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan

    S Shimada, A Ito, Y Kawasaki, N Kakoi, T Taima, K Mitsuzuka & Y Arai

  2. Department of Pathology, Tohoku University Hospital, Miyagi, Japan

    M Watanabe

  3. Department of Urology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

    S Saito

Authors
  1. S Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Kakoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Taima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Mitsuzuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Ito.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimada, S., Ito, A., Kawasaki, Y. et al. Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy. Prostate Cancer Prostatic Dis 17, 199–205 (2014). https://doi.org/10.1038/pcan.2014.9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2014.9

This article is cited by

Search

Advanced search

Quick links